Chrystie Wan Ning Quek

Dr. Chrystie Wan Ning Quek

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Journal of Medical Education and Curricular Development
Verified
Journal Article
Open access
PDF file
DHDaniel Zhihao Hong
Daniel Zhihao Hong
ALAnnabelle Jia Sing Lim
Annabelle Jia Sing Lim
RTRei Tan
Rei Tan
YOYun Ting Ong
Yun Ting Ong
APAnushka Pisupati
Anushka Pisupati
LKLalit Kumar Radha Krishna
Lalit Kumar Radha Krishna
Heralded as a teaching, assessment and reflective tool, and increasingly as a longitudinal and holistic perspective of the educator’s development, medical educator’s portfolios (MEP)s are increasingly employed to evaluate progress, assess for promotions and career switches, used as a reflective tool and as a means of curating educational activities. However, despite its blossoming role, there is significant dissonance in the content and structure of MEPs. As such, a systematic scoping review (SSR) is proposed to identify what is known of MEPs and its contents. Krishna’s Systematic Evidenced Based Approach (SEBA) was adopted to structure this SSR in SEBA of MEPs. SEBA’s constructivist approach and relativist lens allow data from a variety of sources to be considered to paint a holistic picture of available information on MEPs. From the 12 360 abstracts reviewed, 768 full text articles were evaluated, and 79 articles were included. Concurrent thematic and content analysis revealed similar themes and categories including: (1) Definition and Functions of MEPs, (2) Implementing and Assessing MEPs, (3) Strengths and limitations of MEPs and (4) electronic MEPs. This SSR in SEBA proffers a novel 5-staged evidence-based approach to constructing MEPs which allows for consistent application and assessment of MEPs. This 5-stage approach pivots on assessing and verifying the achievement of developmental milestones or ‘micro-competencies’ that facilitate micro-credentialling and effective evaluation of a medical educator’s development and entrust-ability. This allows MEPs to be used as a reflective and collaborative tool and a basis for career planning.

Verified
Journal Article
Open access
PDF file
WZWeizhen Zeng
Weizhen Zeng
新周新尧 周
新尧 周
SYSULAN YU
SULAN YU
RLRuihua Liu
Ruihua Liu
CQChrystie Wan Ning Quek
Chrystie Wan Ning Quek
YFYun Feng
Yun Feng
Primary Sjögren’s syndrome (pSS) is a chronic, systemic autoimmune disease defined by exocrine gland hypofunction resulting in dry eyes and dry mouth. Despite increasing interest in biological therapies for pSS, achieving FDA-approval has been challenging due to numerous complications in the trials. The current literature lacks insight into a molecular-target-based approach to the development of biological therapies. This review focuses on novel research in newly defined drug targets and the latest clinical trials for pSS treatment. A literature search was conducted on ClinicalTrials.gov using the search term “Primary Sjögren’s syndrome”. Articles published in English between 2000 and 2021 were included. Our findings revealed potential targets for pSS treatment in clinical trials and the most recent advances in understanding the molecular mechanisms underlying the pathogenesis of pSS. A prominent gap in current trials is in overlooking the treatment of extraglandular symptoms such as fatigue, depression, and anxiety, which are present in most patients with pSS. Based on dryness and these symptom-directed therapies, emerging biological agents targeting inflammatory cytokines, signal pathways, and immune reaction have been studied and their efficacy and safety have been proven. Novel therapies may complement existing non-pharmacological methods of alleviating symptoms of pSS. Better grading systems that add extraglandular symptoms to gauge disease activity and severity should be created. The future of pSS therapies may lie in gene, stem-cell, and tissue-engineering therapies.

1 November 2020 in JAAD Case Reports
Verified
Journal Article
Open access
CQChrystie Wan Ning Quek
Chrystie Wan Ning Quek
YFYee Wah Foong
Yee Wah Foong
STSiew Kiang Tan
Siew Kiang Tan
SSShui Yen Soh
Shui Yen Soh
PTPoh Lin Tan
Poh Lin Tan
MKMark Jean Aan Koh
Mark Jean Aan Koh

20 January 2026 in Asia-Pacific Journal of Ophthalmology
Verified
Journal Article
Open access
JWJoy Le Yi Wong
Joy Le Yi Wong
HCHaoran Cheng
Haoran Cheng
WPWen Jun Peh
Wen Jun Peh
DHDean Ho
Dean Ho
TWTien Yin Wong
Tien Yin Wong
DTDarren Shu Jeng Ting
Darren Shu Jeng Ting
As the world's population ages, the focus of healthcare is shifting from extending life span to promoting health span. There is an unmet need to identify sensitive and reliable markers of health span through more cost-effective and non-invasive methods, to enable early and effective intervention on modifiable aging factors. The eye offers a unique window into systemic health, providing direct visualization of the body's vascular and neural health. This review presents an overview of how various ocular structures can serve as biomarkers of health span-drawing on insights from ocular imaging, metabolomics, and proteomics, with evidence from basic science, animal models, and human clinical trials. The role of artificial intelligence (AI) in predicting biological age and the risk of age-related systemic conditions is also highlighted, with a focus on current applications and how AI is being integrated to synthesize and interpret multimodal data.

19 October 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
WZWeizhen Zeng
Weizhen Zeng
新周新尧 周
新尧 周
RLRuihua Liu
Ruihua Liu
CQChrystie Wan Ning Quek
Chrystie Wan Ning Quek
VYVincent Ho Chit Yu
Vincent Ho Chit Yu
YFYun Feng
Yun Feng
Primary Sjögren's syndrome (pSS) is a chronic, systemic autoimmune disease defined as exocrine gland hypofunction resulting in dry eyes and dry mouth. Recent interest in biological therapies for pSS has been garnered, however achieving FDA-approval has been challenging due to the numerous complications in the trials. Current literature lacks insight and a molecular target-based approach to the development of biological therapies. This review focuses on novel research in newly defined drug targets and latest clinical trials for pSS treatment. A literature search was conducted on ClinicalTrials.gov using the search term “Primary Sjögren's syndrome”. Articles published between 2000 and 2021 in English language were included. Our findings revealed the potential targets for pSS treatment in clinical trials and the most recent advances in understand-ing of molecular mechanisms underlying the pathogenesis of pSS. A prominent gap in current trials is overlooking the treatment of extraglandular symptoms such as fatigue, depression and anxiety which pervade most patients with pSS. Based on dryness and these symptom-directed therapies, emerging biological agents targeting inflammatory cytokines, signal pathways and immune reaction have been studied and proved the efficacy and safety. Novel therapies may complement existing non-pharmacological methods of alleviating symptoms of pSS. Better grad-ing systems adding extraglandular symptoms to gauge disease activity and severity should be created. The future of pSS therapies may lie in gene therapy, stem cell and tissue engineering ther-apy.

1 July 2023 in Annals of Internal Medicine: Clinical Cases
Verified
Journal Article
Closed access
CNChester Yan Hao Ng
Chester Yan Hao Ng
CQChrystie Wan Ning Quek
Chrystie Wan Ning Quek
YLYi Ting Lim
Yi Ting Lim
JCJiacai Cho
Jiacai Cho